Utility of 18F-FDG PET/CT for predicting pathologic complete response in Hormone receptor-positive, HER2-negative breast cancer patients receiving neoadjuvant chemotherapy [post]

In Hee Lee, Soo Jung Lee, Jeeyeon Lee, Jinhyang Jung, Hoyong Park, Shin Young Jeong, Sang-woo Lee, Yee Soo Chae
2020 unpublished
Background: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) is a predictor of improved outcomes in breast cancer. In patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative breast cancer, the response to NAC is variable and mostly limited. This study was an investigation of the predictive relevance of parameters of 18F-FDG PET/CT for the pCR to NAC in patients with HR-positive, HER2–negative breast cancer. Methods: AH total
more » ... of 109 consecutive HR-positive and HER2-negative breast cancer patients who were treated with NAC were enrolled in this prospective cohort study. The relationships between pretreatment 18F-FDG PET/CT and clinical outcomes including pathologic response to NAC were evaluated. Results: All patients finished their planned NAC cycles and eight patients (7.3%) achieved pCR. In the receiver operating characteristic (ROC) curve analysis, pSUVmax exhibited high sensitivity and specificity for predicting pCR. Furthermore, multivariate logistic regression analysis revealed pSUVmax as a predictive factor for pCR (hazard ratio = 17.452; 95% CI = 1.847 – 164.892; p = 0.013). Conclusion: The results of this study suggest that 18F-FDG PET/CT pSUVmax is a predictive factor for pCR of HR-positive, HER2-negative breast cancer to NAC.
doi:10.21203/rs.3.rs-24641/v2 fatcat:y7atfkjstbclvdq6gfheqbvciu